Shalby Management Change
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.
Shalby reported a modest 11.6% revenue growth with its MetLife business reaching EBITDA break-even, but hospital margins remain under pressure due to new doctor recruitments.
Shalby Limited reported Q1 FY27 consolidated revenue of ₹3,386 mn, up 11.6% YoY, and PAT of ₹105 mn, up 36.7% YoY. Focus remains on orthopedic leadership and expanding implant business.
Shalby Ltd reported revenue from operations of ₹331.2 Cr (+11.7% YoY) and net profit of ₹10.5 Cr (+36.4% YoY) for Q1 FY27.
Shalby Limited reported Q4 FY26 consolidated revenue growth of 9.4% YoY. Key focus on MedTech turnaround with positive EBITDA and expansion in oncology services.
Shalby delivered strong Q4 growth with EBITDA up 43.1% YoY, driven by operational efficiency and recovery in the implant business despite geopolitical headwinds in international segments.
Shalby Limited reports Q4 FY26 consolidated revenue growth of 9.4% YoY. The company is scaling its MedTech implant business and expanding hospital capacity through an asset-light O&M model.
Shalby Limited delivered Q4 FY26 consolidated revenue growth of 9.4% YoY. Strategy focuses on diversifying specialties beyond arthroplasty and expanding the MedTech implant business.
Shalby Ltd reported revenue from operations of ₹287.4 Cr (+8.5% YoY) and net profit of ₹18.5 Cr for Q4 FY26.